Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
Details
Publication Year 2023-06,Volume 21,Issue #3,Page e93-e103
Journal Title
Clinical Genitourinary Cancer
Publication Type
Review
Abstract
Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antiandrogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.
Publisher
Elsevier
Keywords
Male; Humans; *Prostatic Neoplasms/drug therapy/radiotherapy/pathology; Androgen Antagonists/therapeutic use; Hormones; Metastasis-directed therapy; Metastatic prostate cancer; Radiotherapy
Department(s)
Radiation Oncology
PubMed ID
36456467
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-05 06:53:43
Last Modified: 2024-07-09 05:03:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙